Britto, R and Somasundaram, K (2004) Ribozyme’s Potential in Cervical Cancer Control. In: Cancer Biology & Therapy, 3 (11). pp. 1135-1136.
79.pdf - Published Version
Restricted to Registered users only
Download (161Kb) | Request a copy
Cervical cancer is the second commonest cancer in women worldwide, and its predominant causative agent is the Human Papillomavirus (HPV), whose presence is essential for the induction as well as the maintenance of this disease. Neutralizing or checkmating abnormal gene expression with the help of ribozymes is a relatively new technique that has engaged the attention of oncologists for the last fifteen years. Ribozymes are small, catalytic antisense RNA molecules that can bind, cleave and inactivate their complementary target mRNA. It was Cech and co-workers who first reported the possibility of RNA self-splicing in their study of the unicellular organism Tetrahymena thermophilia.1 Then came Uhlenbeck’s actual demonstration of the functioning of a small, active ‘RNA enzyme’, the hammerhead ribozyme.2 These two events provided the impetus for further explorations, leading to the exploitation of RNA enzymes in the war against infectious diseases and cancer.
|Item Type:||Journal Article|
|Additional Information:||Copyright of this article belongs to Landes Bioscience.|
|Keywords:||cervical cancer;human papillomavirus;E6;E7;ribozyme;gene therapy.|
|Department/Centre:||Division of Biological Sciences > Biochemistry
Division of Biological Sciences > Microbiology & Cell Biology
|Date Deposited:||19 Dec 2008 15:17|
|Last Modified:||19 Sep 2010 04:56|
Actions (login required)